We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

88 hedge funds and large institutions have $146M invested in Ovid Therapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more capital invested

Capital invested by funds: $64.5M → $146M (+$81.2M)

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

18% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 22

11.63% more ownership

Funds ownership: 43.51% → 55.14% (+12%)

6% more funds holding

Funds holding: 83 → 88 (+5)

69% less call options, than puts

Call options by funds: $1.25M | Put options by funds: $4.02M

Holders
88
Holders Change
+5
Holders Change %
+6.02%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
26
Reduced
22
Closed
16
Calls
$1.25M
Puts
$4.02M
Net Calls
-$2.77M
Net Calls Change
-$2.27M

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$20.2M
2
SCM
Stonepine Capital Management
Oregon
+$8.25M
3
BI
BVF Inc
California
+$6.3M
4
IC
Ikarian Capital
Texas
+$3.74M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.03M

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$3.35M
2
VC
Vivo Capital
California
-$2.89M
3
BBA
Baker Bros. Advisors
New York
-$2.21M
4
CA
CHI Advisors
New York
-$1.93M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
76
Citigroup
New York
$18K -$20.4K -6,146 -58%
AIP
77
Ameritas Investment Partners
Nebraska
$15K – – –
CG
78
Cutler Group
California
$8K +$6.64K +2,000 +2,000%
OSAM
79
O'Shaughnessy Asset Management
Connecticut
$7K – – –
PAM
80
Panagora Asset Management
Massachusetts
$7K – – –
Bank of Montreal
81
Bank of Montreal
Ontario, Canada
$5K -$20.7K -6,245 -82%
PCM
82
Penserra Capital Management
California
$5K -$50 -15 -1%
Osaic Holdings
83
Osaic Holdings
Arizona
$2K – – –
HR
84
Howe & Rusling
New York
$1K – – –
PC
85
Permanens Capital
New York
$1K – – –
AIG
86
American International Group
New York
$111 +$246 +74 +0.3%
VC
87
Vivo Capital
California
– -$2.89M -1,250,000 Closed
BBA
88
Baker Bros. Advisors
New York
– -$2.21M -955,690 Closed
Renaissance Technologies
89
Renaissance Technologies
New York
– -$1.64M -710,507 Closed
Axa
90
Axa
France
– -$1.43M -620,402 Closed
Two Sigma Investments
91
Two Sigma Investments
New York
– -$799K -345,706 Closed
RCM
92
RA Capital Management
Massachusetts
– -$658K -285,000 Closed
Millennium Management
93
Millennium Management
New York
– -$587K -254,046 Closed
GTCM
94
Gyon Technologies Capital Management
New Jersey
– -$203K -88,008 Closed
Squarepoint
95
Squarepoint
New York
– -$164K -70,987 Closed
VF
96
Virtu Financial
New York
– -$36K -15,625 Closed
CS
97
Credit Suisse
Switzerland
– -$33K -14,568 Closed
Tudor Investment Corp
98
Tudor Investment Corp
Connecticut
– -$32K -13,677 Closed
EGM
99
Engineers Gate Manager
New York
– -$30K -13,000 Closed
LSA
100
Leonteq Securities AG
Switzerland
– -$27.7K -12,000 Closed
1 2 3
4
5

OVID Hedge Fund Activity: Q1 2021 in Review

88 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2021, worth a combined $146M — up 126% from $64.5M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new OVID positions and 16 closed out — a net gain of 6 holders — while 26 added to existing stakes and 22 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $20.2M. The largest seller was UBS Group, cutting an estimated $3.35M.

  • 88 institutional investors held Ovid Therapeutics (OVID) as of Q1 2021, up from 83 in Q4 2020.
  • Funds reported $146M of Ovid Therapeutics stock for Q1 2021, up 126% quarter-over-quarter.
  • 22 funds opened new Ovid Therapeutics positions in Q1 2021 and 16 closed out, a net change of +6 holders.
  • The largest Ovid Therapeutics buyer in Q1 2021 was EcoR1 Capital, an estimated $20.2M added.
  • The largest Ovid Therapeutics seller in Q1 2021 was UBS Group, an estimated $3.35M sold.

Based on aggregated 13F filings for Q1 2021.